SCHEMBL3129488

SCHEMBL3129488

CC(C)Oc1cc(N(Cc2cnco2)c2cccc(C(=O)O)c2)ccc1OC(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 5/20 0.39
RXRB P28702 1/20 0.39
RXRG P48443 1/20 0.39
AAK1 Q2M2I8 2/20 0.35
CIT O14578 1/20 0.35
GAK O14976 1/20 0.35
PRKX P51817 1/20 0.35
PRKCQ Q04759 1/20 0.35
HASPIN Q8TF76 1/20 0.35
MKNK1 Q9BUB5 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
MKNK2 Q9HBH9 1/20 0.35
BMP2K Q9NSY1 1/20 0.35
PDE4D Q08499 3/20 0.35
PDE4A P27815 2/20 0.35
PDE4B Q07343 2/20 0.35
PDE4C Q08493 2/20 0.35
IMPDH2 P12268 1/20 0.34
PPARA Q07869 1/20 0.33
MRGPRX4 Q96LA9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13486391 0.92 RXRA (0.34) RXRARXRBRXRGAAK1CIT
SCHEMBL3131296 0.92 IMPDH2 (0.39) AAK1CITGAKPRKXPRKCQ
SCHEMBL3121148 0.92 IMPDH2 (0.39) AAK1CITGAKPRKXPRKCQ
SCHEMBL3213414 0.92 RXRA (0.48) RXRARXRBRXRGAAK1CIT
SCHEMBL3214257 0.91 RXRA (0.40) RXRARXRBRXRGAAK1PDE4D
SCHEMBL3117544 0.90 HRH4 (0.39) RXRARXRBRXRGAAK1CIT
SCHEMBL3199477 0.89 AAK1 (0.33) RXRARXRBRXRGAAK1CIT
SCHEMBL3208478 0.88 PDE4D (0.39) PDE4DPDE4APDE4BPDE4C
SCHEMBL3194660 0.87 PDE4A (0.40) RXRARXRBRXRGAAK1CIT
SCHEMBL3117619 0.86 RXRA (0.41) RXRARXRBRXRGPDE4DPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B RXRA 2856/4885RXRB 2676/4885RXRG 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.